Health Ministry shocker in RTI reply: CDSCO, ICMR admit to multiple side effects of Covid-19 jabs Farhat Nasim17 Jan 2023 2:04 PM ISTNew Delhi: In a shocking response to an RTI query, the Central Drugs Standard Control Organisation (CDSCO) and Indian Council of Medical Research...
AstraZeneca concludes acquisition of Neogene Therapeutics Ruchika Sharma17 Jan 2023 1:15 PM ISTUK: AstraZeneca has completed the acquisition of Neogene Therapeutics Inc.. Neogene will operate as a wholly-owned subsidiary of AstraZeneca, with...
Asthma treatment: AstraZeneca Tezspire approved for self-administration in EU in new pre-filled pen Ruchika Sharma15 Jan 2023 9:00 AM ISTTezspire will be available as a fixed-dose 210mg subcutaneous injection via a pre-filled, single-use auto-injector (the Tezspire pre-filled pen), in...
AstraZeneca to acquire CinCor Pharma in USD 1.8 billion deal Ruchika Sharma9 Jan 2023 4:35 PM ISTWaltham: CinCor Pharma, Inc. today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to...
USFDA accepts AstraZeneca’s BLA for Nirsevimab for prevention of RSV lower respiratory tract disease Ruchika Sharma7 Jan 2023 10:00 AM ISTRSV is a very contagious virus that can lead to serious respiratory illness, according to the Centers for Disease Control and Prevention.
AstraZeneca Calquence gets Japenese nod for treatment-naïve chronic lymphocytic leukaemia Ruchika Sharma1 Jan 2023 10:00 AM ISTCalquence (acalabrutinib) is a next-generation, selective inhibitor of BTK.
AstraZeneca gets CDSCO panel nod to study anticancer drug Datopotamab deruxtecan Dr. Divya Colin31 Dec 2022 5:45 PM ISTNew Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
GSK, Sanofi, Pfizer and other drugmakers plan to raise prices on at least 350 drugs in US in January Ruchika Sharma31 Dec 2022 1:15 PM ISTTo date, Pfizer announced the most increases, with prices rising on 89 unique drug brands, and an additional increase on 10 drug brands at its Hospira...
AstraZeneca gets Japanese approval for Imfinzi, Imjudo to treat 3 types of cancer Ruchika Sharma28 Dec 2022 11:30 AM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca Forxiga recommended for nod in EU for chronic heart failure Ruchika Sharma20 Dec 2022 5:30 PM ISTHeart failue is a life-threatening chronic disease in which the heart cannot pump enough blood around the body, affecting 15 million people in the EU.
Setback to AstraZeneca: Imfinzi fails as monotherapy for non-small lung cancer Ruchika Sharma20 Dec 2022 1:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Conduct CT in Indian population: CDSCO Panel Tells AstraZeneca for Anifrolumab Dr. Divya Colin19 Dec 2022 6:00 PM ISTNew Delhi: Highlighting that the there is no study data available in Indian population for monoclonal antibody Anifrolumab 150mg/ml concentrate for...
